InMode Ltd. (INMD)
| Market Cap | 887.66M -10.2% |
| Revenue (ttm) | 374.64M -4.5% |
| Net Income | 87.19M -50.4% |
| EPS | 1.36 -40.8% |
| Shares Out | 63.36M |
| PE Ratio | 10.29 |
| Forward PE | 10.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,730 |
| Open | 14.07 |
| Previous Close | 14.10 |
| Day's Range | 13.91 - 14.11 |
| 52-Week Range | 12.72 - 16.74 |
| Beta | 1.97 |
| Analysts | Hold |
| Price Target | 15.50 (+10.64%) |
| Earnings Date | May 6, 2026 |
About INMD
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. The ... [Read more]
Financial Performance
In 2025, InMode's revenue was $370.50 million, a decrease of -6.16% compared to the previous year's $394.82 million. Earnings were $93.83 million, a decrease of -48.24%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for INMD stock is "Hold." The 12-month stock price target is $15.5, which is an increase of 10.64% from the latest price.
News
InMode to Present at Upcoming Investor Conferences and Events
YOKNEAM, Israel, May 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conf...
InMode price target lowered to $14 from $17 at Baird
Baird lowered the firm’s price target on InMode (INMD) to $14 from $17 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results and…
InMode price target lowered to $19 from $21 at Barclays
Barclays lowered the firm’s price target on InMode (INMD) to $19 from $21 and keeps an Overweight rating on the shares.
InMode reports Q1 adjusted EPS 25c, consensus 30c
Reports Q1 revenue $82.02M, consensus $79.86M. “While the macroeconomic environment remains challenging, our total revenue this quarter reached our expectations, however our profitability was lower th...
InMode sees FY26 adjusted EPS $1.33-$1.38, consensus $1.45
Sees FY26 revenue $365M-$375M, consensus $370.04M. Non-GAAP gross margin between 74%-76%.
InMode CFO Yair Malca steps down
Yair Malca has stepped down from his role as CFO, effective May 5. To support a smooth transition, Malca will remain engaged with the company in a consulting capacity for…
InMode Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 5% year-over-year to $82M, led by U.S. strength, while gross margin declined due to product mix and higher expenses. Guidance for 2026 remains steady, with ongoing share buybacks and exploration of M&A as market competition intensifies.
InMode Earnings release: Q1 2026
InMode released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
InMode Slides: Q1 2026
InMode has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for...
Weight-loss revolution sparks new appetite for aesthetics firms
Aesthetic firms are betting that a growing pool of patients experiencing loose skin and facial volume loss from GLP-1 obesity drugs will fuel a new wave of demand, as the sector heads into first-quart...
InMode Transcript: 25th Annual Needham Virtual Healthcare Conference
Q1 growth was driven by new product launches, but gross margins declined due to higher costs and increased competition. The company is expanding its product portfolio and international presence, while ongoing clinical studies and regulatory submissions target future growth. Guidance for 2026 remains cautious.
InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd.
InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer an...
InMode Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Operations face ongoing disruptions in Israel, with manufacturing at 60% capacity and logistics strained. Over $600 million has been returned via buybacks, while M&A targets focus on complementary tech and Asia. Growth is expected to resume in 2027, supported by new products and organizational restructuring.
InMode announces new share repurchase program
InMode (INMD) announced that its Board of Directors has authorized a new share repurchase program for up to approximately 10% of the company’s total shares outstanding, representing approximately 6.38...
InMode Announces New Share Repurchase Program
YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a n...
InMode Transcript: Barclays 28th Annual Global Healthcare Conference
After two years of decline, expectations are for a flat top line in 2026, with organizational restructuring and new product launches aimed at supporting recovery. Margin pressures persist due to laser commoditization, but growth in new verticals and a focus on North America are key strategies.
InMode to Present at Upcoming Investor Conferences
YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor con...
InMode’s independent transaction committee determines to discontinue process
InMode (INMD) announced that the independent transaction committee of its Board of Directors has completed its review of proposals received in connection with a potential transaction. Following review...
InMode Announces Conclusion of Independent Transaction Committee Review
YOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent...
InMode price target raised to $17 from $16 at Baird
Baird analyst Jeff Johnson raised the firm’s price target on InMode (INMD) to $17 from $16 and keeps a Neutral rating on the shares. The firm updated its model following…
InMode Earnings Call Transcript: Q4 2025
Q4 2025 revenue rose year-over-year, but full-year sales declined 6% amid industry softness. International sales grew, while gross margins and EPS declined due to product mix and new laser launches. 2026 is expected to be a stabilization year, with new products and strategic alternatives under review.
InMode Earnings release: Q4 2025
InMode released its Q4 2025 earnings on February 10, 2026, summarizing the period's financial results.
InMode Annual report: Q4 2025
InMode has published its Q4 2025 annual report on February 10, 2026.